hVIVO (LON:HVO - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at Shore Capital in a report released on Thursday, Marketbeat Ratings reports.
hVIVO Price Performance
Shares of HVO stock traded up GBX 0.15 ($0.00) during trading hours on Thursday, reaching GBX 16.40 ($0.22). The company had a trading volume of 1,368,712 shares, compared to its average volume of 3,222,340. hVIVO has a 12-month low of GBX 12.60 ($0.17) and a 12-month high of GBX 31 ($0.41). The company has a market capitalization of £116.04 million, a price-to-earnings ratio of 6.76 and a beta of 0.97. The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The stock has a fifty day moving average of GBX 16.03 and a 200-day moving average of GBX 20.64.
hVIVO (LON:HVO - Get Free Report) last announced its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. On average, equities analysts anticipate that hVIVO will post 1.5492958 earnings per share for the current year.
Insider Buying and Selling
In related news, insider Yamin Mo' Khan sold 3,062,246 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.22), for a total transaction of £520,581.82 ($686,421.18). 14.03% of the stock is currently owned by company insiders.
hVIVO Company Profile
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Featured Stories
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
